Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析

◆英語タイトル:Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1680
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥14,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Protalix BioTherapeutics Inc (PLX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s marketed product, Elelyso (taliglucerase alfa) is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of Fabry disease; cystic fibrosis, inflammatory bowel diseases (IBD) and Gout. Protalix develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology, ProCellEx protein expression system. Protalix is headquartered in Carmiel, Israel.

Protalix BioTherapeutics Inc Key Recent Developments

Mar 12,2020 Protalix BioTherapeutics reports fourth quarter and full year 2019 financial and business results
Dec 19,2019 Protalix BioTherapeutics adds two accomplished biopharmaceutical executives to its board of directors
Nov 07,2019 Protalix BioTherapeutics reports third quarter 2019 results and provides corporate update
Aug 22,2019 Protalix BioTherapeutics focuses on evaluating and pursuing alternatives to maximize shareholder value through refinancing & strategic partnerships

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Protalix BioTherapeutics Inc – Key Facts
Protalix BioTherapeutics Inc – Key Employees
Protalix BioTherapeutics Inc – Major Products and Services
Protalix BioTherapeutics Inc – History
Protalix BioTherapeutics Inc – Company Statement
Protalix BioTherapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Protalix BioTherapeutics Inc – Business Description
Protalix BioTherapeutics Inc – Corporate Strategy
Protalix BioTherapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Protalix BioTherapeutics Inc – Strengths
Protalix BioTherapeutics Inc – Weaknesses
Protalix BioTherapeutics Inc – Opportunities
Protalix BioTherapeutics Inc – Threats
Protalix BioTherapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Protalix BioTherapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 12, 2020: Protalix BioTherapeutics reports fourth quarter and full year 2019 financial and business results
Dec 19, 2019: Protalix BioTherapeutics adds two accomplished biopharmaceutical executives to its board of directors
Nov 07, 2019: Protalix BioTherapeutics reports third quarter 2019 results and provides corporate update
Aug 22, 2019: Protalix BioTherapeutics focuses on evaluating and pursuing alternatives to maximize shareholder value through refinancing & strategic partnerships
Aug 13, 2019: Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
Aug 08, 2019: Protalix BioTherapeutics reports second quarter 2019 results and provides corporate update
Jul 29, 2019: Protalix BioTherapeutics appoints Eyal Rubin as its new Senior Vice President and Chief Financial Officer
Jul 22, 2019: Protalix BioTherapeutics: Departure of Directors or certain officers; election of Directors; appointment of certain officers; compensatory arrangements of certain officers
May 21, 2019: Protalix BioTherapeutics appoints Dror Bashan as its New President and Chief Executive Officer and Director
May 06, 2019: Protalix Biotherapeutics reports 2019 first quarter results and provides corporate update
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Protalix BioTherapeutics Inc, Key Facts
Protalix BioTherapeutics Inc, Key Employees
Protalix BioTherapeutics Inc, Major Products and Services
Protalix BioTherapeutics Inc, History
Protalix BioTherapeutics Inc, Subsidiaries
Protalix BioTherapeutics Inc, Key Competitors
Protalix BioTherapeutics Inc, Ratios based on current share price
Protalix BioTherapeutics Inc, Annual Ratios
Protalix BioTherapeutics Inc, Annual Ratios (Cont...1)
Protalix BioTherapeutics Inc, Interim Ratios
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Protalix BioTherapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Protalix BioTherapeutics Inc, Performance Chart (2015 - 2019)
Protalix BioTherapeutics Inc, Ratio Charts
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NeuroScientific Biopharmaceuticals Ltd (NSB):企業の財務・戦略的SWOT分析
    NeuroScientific Biopharmaceuticals Ltd (NSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Tokyu Corp:企業の戦略・SWOT・財務分析
    Tokyu Corp - Strategy, SWOT and Corporate Finance Report Summary Tokyu Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Thar Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Thar Pharmaceuticals Inc (Thar Pharma), a subsidiary of Grunenthal GmbH is a healthcare solution provider that concentrates on transforming intravenous (IV) drugs into oral drugs for existing and new indications. The company’s lead product T121, an oral form of IV only zoledronic acid, is de …
  • Safran Nacelles Ltd :企業の戦略・SWOT・財務情報
    Safran Nacelles Ltd - Strategy, SWOT and Corporate Finance Report Summary Safran Nacelles Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Entertainment One Ltd.:企業の戦略・SWOT・財務分析
    Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report Summary Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Antero Resources Corporation (AR)-石油・ガス分野:企業M&A・提携分析
    Summary Antero Resources Corporation (Antero), formerly Antero Resources Appalachian Corporation, is an independent oil and natural gas company that carries out exploration, development, production and acquisition of natural gas, natural gas liquids (NGLs) and oil properties in the Appalachia Basin. …
  • Exfo Inc.:企業の戦略・SWOT・財務分析
    Exfo Inc. - Strategy, SWOT and Corporate Finance Report Summary Exfo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Safe Orthopaedics SA (SAFOR):医療機器:M&Aディール及び事業提携情報
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical device company that manufactures and markets devices for spinal surgery. The company’s products comprise implants and surgical instruments. It offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws, per …
  • Zen Technologies Limited
    Zen Technologies Limited - Strategy, SWOT and Corporate Finance Report Summary Zen Technologies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Greensmith Energy Management Systems LLC:電力:M&Aディール及び事業提携情報
    Summary Greensmith Energy Management Systems, LLC (Greensmith), a subsidiary of Wartsila Corporation, is a provider of energy storage management and services. The company specializes in software and control solutions to operate and manage Distributed Energy Storage Systems (DESS) for utility-scale, …
  • Jamaica Public Service Co Ltd:企業の戦略的SWOT分析
    Jamaica Public Service Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • NovImmune SA-製薬・医療分野:企業M&A・提携分析
    Summary NovImmune SA (NovImmune) is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company develops pipeline products using its proprietary mAb generating platform, DiversityTrap and ka …
  • GENTEX Corp:企業の戦略的SWOT分析
    GENTEX Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Nanobiotix SA (NANO):企業の財務・戦略的SWOT分析
    Summary Nanobiotix SA (Nanobiotix) is a late stage clinical company which develops nanomedicines for the treatment of cancers. The company develops first-in-class products utilizing its proprietary technology NanoXray, based on the physical mode of action of nanoparticles that increase the X-rays do …
  • Tabcorp Holdings Limited (TAH):企業の財務・戦略的SWOT分析
    Tabcorp Holdings Limited (TAH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Silver Bull Resources, Inc.:企業の戦略・SWOT・財務情報
    Silver Bull Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Silver Bull Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Range Resources Ltd (RRS):企業の財務・戦略的SWOT分析
    Range Resources Ltd (RRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Imbed Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Imbed Biosciences Inc (Imbed) is a medical device company which develops technologies for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. The company’s product platform, a polymeric Microfilm develops bioactive molecules on tissue surfaces to manage wou …
  • Japan Airlines Co Ltd:企業の戦略・SWOT・財務情報
    Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Seres Therapeutics Inc (MCRB):企業の財務・戦略的SWOT分析
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆